279 related articles for article (PubMed ID: 21913035)
1. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM
Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035
[TBL] [Abstract][Full Text] [Related]
2. A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment.
Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Pan L; Tighiouart M; Shin HJ; Koenig L; Park W; Rycroft D; Nannapaneni S; Wang Y; Chen ZG; Shin DM
Int J Cancer; 2012 Aug; 131(4):956-69. PubMed ID: 21918971
[TBL] [Abstract][Full Text] [Related]
3. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Oyen WJ; van der Graaf WT; van Laarhoven HW
Int J Cancer; 2013 Jul; 133(2):307-14. PubMed ID: 23335047
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
Tonra JR; Deevi DS; Corcoran E; Li H; Wang S; Carrick FE; Hicklin DJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2197-207. PubMed ID: 16609035
[TBL] [Abstract][Full Text] [Related]
6. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.
Damiano V; Caputo R; Garofalo S; Bianco R; Rosa R; Merola G; Gelardi T; Racioppi L; Fontanini G; De Placido S; Kandimalla ER; Agrawal S; Ciardiello F; Tortora G
Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12468-73. PubMed ID: 17636117
[TBL] [Abstract][Full Text] [Related]
7. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
[TBL] [Abstract][Full Text] [Related]
8. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma.
Prichard CN; Kim S; Yazici YD; Doan DD; Jasser SA; Mandal M; Myers JN
Laryngoscope; 2007 Apr; 117(4):674-9. PubMed ID: 17429874
[TBL] [Abstract][Full Text] [Related]
9. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
10. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases.
Dong X; Jin K; Hu X; Du F; Lan H; Han N; Ma Z; Xie B; Cui B; Teng L; Cao F
Int J Mol Med; 2012 Jul; 30(1):126-32. PubMed ID: 22505231
[TBL] [Abstract][Full Text] [Related]
12. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
13. Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Wong TW; Kramer RA; Wild R; Lee FY
Clin Cancer Res; 2005 Aug; 11(15):5558-65. PubMed ID: 16061873
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expression.
Heskamp S; Boerman OC; Molkenboer-Kuenen JD; Sweep FC; Geurts-Moespot A; Engelhardt MS; van der Graaf WT; Oyen WJ; van Laarhoven HW
Mol Pharm; 2014 Nov; 11(11):4249-57. PubMed ID: 25294389
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
[TBL] [Abstract][Full Text] [Related]
16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
17. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
18. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
Gyanchandani R; Sano D; Ortega Alves MV; Klein JD; Knapick BA; Oh S; Myers JN; Kim S
Oral Oncol; 2013 Aug; 49(8):761-70. PubMed ID: 23623402
[TBL] [Abstract][Full Text] [Related]
20. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK
Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
